In the case of lung cancer, it is well known that EGFR-activating mutations can be used as a biomarker to stratify patients for EGFR TKI treatment as lung cancer harboring EGFR mutations is addicted to EGFR activation and thus sensitive to EGFR TKIs. The gene discussed is EGFR; the disease is lung carcinoma.